1[1]Packer M.Beta-blockade in the treatment of chronic heart failure.Eur Heart J,1996,17:21～23.
2[2]Waagstein E,Bristow MR,Swedberg K,et al.For the Metoprolol in Dilated Cardiomyopathy(MDC)trial study group.Beneficial effects of metoprolol in idlated cardiomyopathy.Lacet,1993,329:149～155.
3[3]MERITT-HF Study Group.Effect of metoprolol CR/XL in chponic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure(MERIT-HF).Lacet,1999,352:2001～2007.
4[4]CIBIS Investigators and Committees.A randomized trial of beta-blockade in heart failure.Circulation,1994,90:1765～1773.
5[5]CIBIS-Ⅱ Inbesstigators and Committees.Cardiac Insufficiency Bisoprolol Study(CIBIS-Ⅱ):a randomised trial.Lancet,1999,353:9～13.
6[6]Packer M,Brisstow MR,Cohn,et al.The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.N Engl J Med,1996,334:1349～1355.
7[7]Witte K,Thackray S,Banerjee T,et al.Update of ELITE-Ⅱ,BEST,CHAMP,and IMPRESS clinical in heart failure.Eur J Heart Failure,2000,2:107～112.
8[8]Gilbert EM,Colucci WS,Fowler WS,et al.Carvediol without ACE-inhibition in the treatment of patients with moderate to severt chronic heart failure.Circulation,1996,94:suppl 1:1～663.
